It’s been a crucial week for Abbott Laboratories (NYSE:ABT); here’s what analysts have to say.

Abbott Laboratories (NYSE:ABT) Logo
Investors sentiment increased to 0.89 in Q2 2019. Its up 0.07, from 0.82 in 2019Q1. It is positive, as 46 investors sold Abbott Laboratories shares while 589 reduced holdings. 120 funds opened positions while 443 raised stakes. 1.26 billion shares or 0.12% less from 1.26 billion shares in 2019Q1 were reported.
Verity Asset Mngmt Inc has invested 0.37% in Abbott Laboratories (NYSE:ABT). Moreover, Canada Pension Plan Invest Board has 0.36% invested in Abbott Laboratories (NYSE:ABT) for 2.15M shares. Newman Dignan & Sheerar Incorporated reported 6,621 shares stake. Armstrong Henry H Associate Inc holds 30,227 shares or 0.35% of its portfolio. Hilton Capital Mgmt Ltd holds 2,160 shares. Barrett Asset Limited Liability Corporation reported 108,629 shares stake. Raymond James Tru Na owns 153,062 shares. Pacific Global Investment Mgmt stated it has 0.45% of its portfolio in Abbott Laboratories (NYSE:ABT). Oppenheimer & invested in 105,876 shares. Sector Gamma As has invested 9.29% in Abbott Laboratories (NYSE:ABT). Moreover, Obermeyer Wood Investment Counsel Lllp has 0.06% invested in Abbott Laboratories (NYSE:ABT). The United Kingdom-based River & Mercantile Asset Mgmt Llp has invested 0.02% in Abbott Laboratories (NYSE:ABT). Profund Advsrs Limited Liability Corporation holds 0.21% or 52,077 shares in its portfolio. Assetmark accumulated 2,916 shares or 0% of the stock. Cambridge Communication invested in 0.34% or 70,288 shares.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 4 analysts covering Abbott Labs (NYSE:ABT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abbott Labs has $9400 highest and $86 lowest target. $91.40’s average target is 8.60% above currents $84.16 stock price. Abbott Labs had 11 analyst reports since March 14, 2019 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, March 14 with “Buy”. The firm has “Outperform” rating given on Thursday, June 13 by Wells Fargo. On Tuesday, July 16 the stock rating was maintained by Morgan Stanley with “Overweight”. As per Thursday, July 18, the company rating was maintained by BMO Capital Markets. Raymond James maintained it with “Outperform” rating and $9300 target in Thursday, July 18 report. Below is a list of Abbott Laboratories (NYSE:ABT) latest ratings and price target changes.

18/07/2019 Broker: BMO Capital Markets Rating: Outperform Old Target: $87.0000 New Target: $94.0000 Maintain
18/07/2019 Broker: Raymond James Rating: Outperform Old Target: $87.0000 New Target: $93.0000 Maintain
16/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $85.0000 New Target: $93.0000 Maintain
21/06/2019 Broker: Wells Fargo Rating: Buy Maintain
13/06/2019 Broker: Wells Fargo Rating: Outperform Old Target: $89.0000 New Target: $91.0000 Maintain
30/04/2019 Broker: BidaskScore Rating: Buy Upgrade
16/04/2019 Broker: BidaskScore Rating: Hold Downgrade
09/04/2019 Broker: BidaskScore Rating: Buy Downgrade
22/03/2019 Broker: Wells Fargo Rating: Buy Maintain
14/03/2019 Broker: Cowen & Co Rating: Buy New Target: $86 Maintain

The stock decreased 1.23% or $1.05 during the last trading session, reaching $84.16. About 2.57 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 33.65% since September 13, 2018 and is uptrending. It has outperformed by 33.65% the S&P500.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $148.74 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 51.76 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Finance.Yahoo.com which released: “Is Abbott Laboratories (NYSE:ABT) Investing Your Capital Efficiently? – Yahoo Finance” on July 02, 2019, also Seekingalpha.com with their article: “University of California sues Abbott over probiotic – Seeking Alpha” published on August 30, 2019, Finance.Yahoo.com published: “Should Abbott Laboratories (NYSE:ABT) Be Part Of Your Dividend Portfolio? – Yahoo Finance” on May 18, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Finance.Yahoo.com and their article: “At US$78.27, Is It Time To Put Abbott Laboratories (NYSE:ABT) On Your Watch List? – Yahoo Finance” published on May 01, 2019 as well as Finance.Yahoo.com‘s news article titled: “Can We See Significant Institutional Ownership On The Abbott Laboratories (NYSE:ABT) Share Register? – Yahoo Finance” with publication date: August 05, 2019.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.